Lilly banks on Elanco


%u201CThis is another example of how Elanco is becoming a more important part of Eli Lilly,%u201D said William Weldon, Elanco%u2019s vice president of global research and development. Elanco already has operations around the world. With the acquisition of Novartis Animal Health, that reach will be even greater. (Tom Russo / Daily Reporter)

Eli Lilly and Co. has agreed to pay $5.4 billion in cash for Novartis Animal Health in the second-largest deal in Lilly's history. (Tom Russo / Daily Reporter)

GREENFIELD — Elanco Animal Health solidified itself Tuesday as the rising star of Eli Lilly and Co.

In what Elanco and Lilly officials called one of the most significant moves in the companies’ histories, Lilly announced a $5.4 billion acquisition that will make its Greenfield-based animal health division a global titan in developing and producing foods and medicine for even more species ranging from canines to cattle to catfish.

The full story is available to subscribers only.

Subscribers can read the entire story online by signing in here.

Not a subscriber? Become one today by clicking here.

All content copyright ©2015 Daily Reporter, a division of Home News Enterprises unless otherwise noted.
All rights reserved. Click here to read our privacy policy.
Daily Reporter • 22 W. New Road • Greenfield, IN 46140 • (317) 462-5528